Different monoclonal antibodies and immunosuppressants administration in patients with Neuromyelitis Optica Spectrum Disorder: A Bayesian Network Meta-Analysis

Abstract

Review question / Objective: (1) participants: adult patients over 18 years with NMOSD; (2) intervention: monoclonal antibodies and immunosuppressants in patients with NMOSD; (3) outcomes: efficacy outcomes included annualized rate of relapse (ARR), EDSS score, relapse rates; Safety outcomes contains adverse events (AEs), gastrointestinal intolerance, leukopenia, hepatotoxicity; (4) study type: RCT and cohort studies. Condition being studied: Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory neurological disorder which is common in neurological department. Current studies did not reveal the efficacy and safety of various monoclonal antibodies and immunosuppressants in patients with NMOSD. The aim of our study is to evaluate which drug intervention is the optimal therapy for NMOSD in controlling relapse, ARR and EDSS based on clinical evidence so far. In our study, we concluded the most effective and most safe drugs in NMOSD patients and made a rank probability of currently used antibodies and immunosuppressants. INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 04 December 2022 and was last updated on 04 December 2022 (registration number INPLASY2022120018).